# STI-3258

Source: https://onco.cc/drugs/sti-3258/  
OnCo record `sti-3258` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first registered STI-3258 TROP-2 study was withdrawn before enrolling any participants.

## Summary

NCT05060276 describes an anti-TROP2 antibody-drug conjugate phase 1 study, withdrawn with zero actual participants because the protocol changed to phase 2. Withdrawal of this study is not evidence of clinical inefficacy or proof that the entire asset was abandoned.

## Fields

- Kind: Treatment
- Status: historic
- Last checked: 2026-10-06
- Modality: Antibody-drug conjugate
- Mechanism: Anti-TROP2 antibody-drug conjugate described in NCT05060276.

## Sources

- ClinicalTrials.gov NCT05060276: https://clinicaltrials.gov/study/NCT05060276

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors](https://onco.cc/trials/nct05060276/)

---
JSON: https://onco.cc/api/v1/entities/sti-3258.json